Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
Press releases
Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST
Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...
Abliva intends to start a pivotal KL1333 study second half 2021
Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...
Abliva AB Interim Report January – June 2020
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner